Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|5|E100-E101

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.5, 2015-05, pp. : E100-E101

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia

By  

Case Reports in Oncology, Vol. 8, Iss. 1, 2015-03 ,pp. : 122-127

Karger

Access to resources Recommend Favorite

Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events

By Capri Stefano   Perlini Stefano  

Current Medical Research and Opinion, Vol. 21, Iss. 6, 2005-06 ,pp. : 913-922

Informa Healthcare

Access to resources Recommend Favorite

Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

By Yood Marianne Ulcickas   Oliveria Susan A.   Cziraky Mark   Hirji Ishan   Hamdan Muhammad   Davis Catherine  

Current Medical Research and Opinion, Vol. 28, Iss. 2, 2012-02 ,pp. : 213-219

Informa Healthcare

Access to resources Recommend Favorite

Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines

By Neelakantan Pratap   Apperley Jane F  

Clinical Practice, Vol. 10, Iss. 3, 2013-05 ,pp. : 283-291

Future Medicine

Access to resources Recommend Favorite

Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 16, Iss. 1, 2018-01 ,pp. : 65-73

John Wiley & Sons Inc

Access to resources Recommend Favorite